Regulus Therapeutics (NASDAQ: RGLS) is one of 186 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its competitors? We will compare Regulus Therapeutics to similar companies based on the strength of its risk, valuation, earnings, institutional ownership, profitability, analyst recommendations and dividends.
Valuation & Earnings
This table compares Regulus Therapeutics and its competitors revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Regulus Therapeutics||$1.19 million||-$81.83 million||-0.68|
|Regulus Therapeutics Competitors||$217.29 million||-$39.39 million||-70.56|
Regulus Therapeutics’ competitors have higher revenue and earnings than Regulus Therapeutics. Regulus Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
This table compares Regulus Therapeutics and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Regulus Therapeutics Competitors||-3,328.05%||-99.40%||-39.42%|
Institutional and Insider Ownership
59.4% of Regulus Therapeutics shares are held by institutional investors. Comparatively, 49.8% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 4.8% of Regulus Therapeutics shares are held by company insiders. Comparatively, 14.7% of shares of all “Biotechnology & Medical Research” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
This is a breakdown of recent recommendations and price targets for Regulus Therapeutics and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Regulus Therapeutics Competitors||535||2429||6605||123||2.65|
Regulus Therapeutics presently has a consensus price target of $2.88, indicating a potential upside of 212.50%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 18.27%. Given Regulus Therapeutics’ higher probable upside, equities research analysts clearly believe Regulus Therapeutics is more favorable than its competitors.
Volatility and Risk
Regulus Therapeutics has a beta of 1.53, suggesting that its share price is 53% more volatile than the S&P 500. Comparatively, Regulus Therapeutics’ competitors have a beta of 1.58, suggesting that their average share price is 58% more volatile than the S&P 500.
Regulus Therapeutics competitors beat Regulus Therapeutics on 10 of the 12 factors compared.
Regulus Therapeutics Company Profile
Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. The Company’s Regulus microMarkers division is focused on identifying microRNAs as biomarkers of human disease. It has a research collaboration with Biogen focused on the discovery of microRNAs as biomarkers for multiple sclerosis and has completed research for another pharmaceutical company to explore microRNAs as biomarkers for specific patient populations. The Company is developing RG-101, an N-Acetylgalactosamine (GalNAc)-conjugated anti-miR targeting miR-122; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, and RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107.
Receive News & Ratings for Regulus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.